Every-8-weeks injectable cabotegravir and rilpivirine is superior to daily oral tenofovir disoproxil fumarate/ lamivudine/ dolutegravir in adolescents living with HIV in sub-Saharan Africa: LATA 96-week results

05 Aug, 2026

Authors: Bwakura Dangarembizi M, Chappell E, Kekitiinwa AR, Kityo C, Siika A, Archary M, Jafta L, Mujuru HA, Anena LD, Nakabuye S, Kiilu C, Mngqibisa R, Akabwai G, Mugerwa H, Walker S, Seeley J, Burger D, Omar A, Bamford A, South A, Nguyen H, Giaquinto C, Spittle B, Ford D, Pett S; LATA Trial Team.

Presented at: AIDS 2026